Last reviewed · How we verify

Erbitux — Competitive Intelligence Brief

Erbitux (Erbitux) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Epidermal growth factor receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Erbitux (Erbitux) — Hellenic Oncology Research Group.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Erbitux TARGET Erbitux Hellenic Oncology Research Group marketed Epidermal growth factor receptor
Vizimpro dacomitinib Pfizer marketed Epidermal growth factor receptor 2018-01-01
Portrazza NECITUMUMAB Eli Lilly Co marketed Epidermal Growth Factor Receptor Antagonist [EPC] Epidermal growth factor receptor 2015-01-01
Gilotrif afatinib Boehringer Ingelheim marketed Kinase Inhibitor [EPC] Epidermal growth factor receptor 2013-01-01
Tykerb LAPATINIB Novartis marketed Kinase Inhibitor Epidermal growth factor receptor 2007-01-01
Tarceva erlotinib Osi Pharms marketed Kinase Inhibitor Epidermal growth factor receptor 2004-01-01
Erbitux cetuximab Imclone marketed Epidermal Growth Factor Receptor Antagonist [EPC] Epidermal growth factor receptor 2004-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erbitux — Competitive Intelligence Brief. https://druglandscape.com/ci/erbitux. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: